Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals (RCE) RCE 327 Gel shows promise in treating multiple antibiotic-resistant infections under the TGA SAS Category A
- The gel achieved a >99.99 per cent reduction against MRSA in an ex-vivo burn wound study
- Clinical trial preparations are underway for various unmet medical needs
- The company aims to combat antibiotic resistance and offer new hope in the fight against drug-resistant superbugs
- RCE is up 13.9 per cent, trading at 69.5 cents at 10:32 am AEST
Recce Pharmaceuticals (RCE) has made further progress in its mission to develop a new class of synthetic anti-infectives.
The company’s RECCE 327 Gel (R327G) has shown promise in treating multiple antibiotic-resistant infections under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS) Category A.
In the initial ex-vivo burn wound study, R327G demonstrated remarkable efficacy against Methicillin-resistant Staphylococcus aureus (MRSA), a serious hospital-acquired infection causing morbidity and mortality.
The gel formulation achieved a 4 to 5-log reduction (>99.99 per cent) against MRSA, making it a potential breakthrough in combating antibiotic resistance.
Two patient case studies highlight the gel’s effectiveness in treating antibiotic-resistant gram-positive and gram-negative bacterial infections.
In one case, a 70-75-year-old male with a puncture wound saw significant improvement after a single application of R327G, avoiding the need for surgical intervention.
Another case involved a 72-year-old male with type 2 diabetes, where the gel effectively healed a wound and averted the possibility of limb amputation.
Recce Pharmaceuticals is actively preparing for clinical trials across various unmet medical needs.
“To see Recce making a difference to patients in such great medical need before us is another welcomed sign of new hope in the fight against drug-resistant superbugs,” RCE CEO James Graham said.
“We look forward to building upon these successes among the present and future clinical trials ahead.”
Recce Pharmaceuticals’ collaboration with Linnaeus Bioscience has provided insight into the gel’s antimicrobial activity.
RCE was up 13.9 per cent, trading at 69.5 cents at 10:32 am AEST.
